20th January to 21st January 2020,
London, United Kingdom

SMi group presents the launch of the inaugural Disruptive Technologies in Pharma conference taking place in London on 20th-21st January, 2020.

We are running this conference because....

McKinsey estimates that big data and machine learning could generate up to $100bn in pharma and medicine annually. There has never been a more pressing need for pharma to transition to digital as existing technologies are being disrupted by Artificial Intelligence, Machine Learning, Internet of Things and Blockchain, while newer categories such as Prescription Digital Therapeutics begin to offer truly disruptive benefits.

As new technologies are being incorporated into pharma it is crucial, we reflect on trends in cutting-edge innovation and explore new tech-enabled opportunities to cut costs and save time.

Partnerships are at the heart of digital transformation. Innovative approaches to partnerships are leading the way towards more effective data collection, faster R&D, seamless clinical trials and above all, more patient-centric medicine.

Conference
programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

Professor Brian D Smith is the world’s leading authority on the evolution of the life sciences industry. At the University of Hertfordshire and Bocconi University, his research group uses Darwinian science to the understand the speciation of business models in the life sciences. His more than 300 articles and books include “The Future of Pharma”, “Brand Therapy”, “Darwin’s Medicine” and, most recently “Leadership in the Life Sciences”. Prior to his academic career, Brian worked in pharma and medtech for 20 years as a Research Chemist and in commercial roles. He continues to advise many of the industry’s leading firms.

• Nonsensical changes in our markets and industry
• Grandeur in our view of the pharma and medtech sectors
• Disruptive innovation as seen from HMS Beagle
• There is nothing as practical as a good theory

• What current trends are shaping the Digital Transformation in healthcare?
• Which technologies are key to transformation?
• How can novel technologies improve patient centricity and clinical success rates?
• What organizational changes are required for the convergence of Pharma and Technology in the new PharmaTec

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

Dr. Shikta Das is an academic, data scientist and women in tech campaigner whose work focuses on providing evidence-based learning in medicine and the pharmaceutical sector. She has worked as a Data Analytics Specialist at Roche Pharmaceuticals, which is the world's third-largest pharmaceutical company, famous for its cancer and diabetes management drugs. She is also an honorary lecturer in Epidemiology and Data Science at University College London (UCL) where she leads metabolomics and data science research within the Medical Research Council's Life-Long Health and Ageing Group. She also teaches essential employability skills to MBBS and MSc Cardiovascular Students on Statistics and Epidemiology at UCL.

Bhushan Bonde, Head of IT - Early Solution Innovation Development, UCBView Bio

Bhushan Bonde is the Head of Innovation Development at IT-NewMeds, UCB. He received PhD in Systems Biology and Mathematical Modelling, with an interdisciplinary background of Computing, Biology and Mathematical Biology from Oxford (2006). He also had an interdisciplinary M. Tech in Bioprocess technology/Chemical Eng. (2001) and Bachelors in Pharmacy (1998) and had been working across Industry, University and Government Research Institutes with 15 years of experience in Computational Biology.

In 2014 he joined UCB in the New Medicines IT team, currently leading the data integration, Image and ‘omics’ based data management and analytics. His research interest involves biological data mining and visualization, mathematical algorithm design, High Performance Scientific Computing and simulation modelling of biological systems. In addition, he is always looking for disruptive technologies such as next generation sequencing and post NGS target validation (e.g. ENCODE), NoSQL techniques for Data Integration (Neo4j, SAP-HANA, SciDB, MongoDB), Gene Signature based mapping for Drug repurposing and Causal Reasoning for target identification, Artificial intelligence and Machine Learning for RWE, digital/sensors data and biological imaging.

Professor Brian D Smith is the world’s leading authority on the evolution of the life sciences industry. At the University of Hertfordshire and Bocconi University, his research group uses Darwinian science to the understand the speciation of business models in the life sciences. His more than 300 articles and books include “The Future of Pharma”, “Brand Therapy”, “Darwin’s Medicine” and, most recently “Leadership in the Life Sciences”. Prior to his academic career, Brian worked in pharma and medtech for 20 years as a Research Chemist and in commercial roles. He continues to advise many of the industry’s leading firms.

Over the past nine years Ian has been working in various segments of the healthcare industry, throughout this time he has been utilizing big data, cutting-edge software and novel technology to find solutions to questions from all ranges of customers from line functions to senior management. Prior to Novartis, he worked in a variety of roles in healthcare, focusing primarily on scientific research and process optimization.

10:30 Morning Coffee

Viktoria Wegscheider is Business Development Specialist at Innerspace – The Deep Training Company. She is the voice of the customer in her company and responsible for use case evaluations of DeepTraining in Virtual Reality. Trained as a graduate researcher in Human Computer Interaction and a Master in IT-Management, she has gained experience in the medical device and pharmaceutical industry. Today, her core competence focuses on the evaluation of potential training use cases for experience-based trainings (e.g. Virtual Reality technology) that lead to high transfer efficacy for the pharmaceutical industry. Innerspace – The DeepTraining Company brings a new, psychologically profound and technologically advanced approach to design and implement trainings on the market. The DeepTraining approach is centered around the “Human Error” and is designed to prevent them in aseptic manufacturing in an effective and efficient way.

Bhushan Bonde, Head of IT - Early Solution Innovation Development, UCBView Bio

Bhushan Bonde is the Head of Innovation Development at IT-NewMeds, UCB. He received PhD in Systems Biology and Mathematical Modelling, with an interdisciplinary background of Computing, Biology and Mathematical Biology from Oxford (2006). He also had an interdisciplinary M. Tech in Bioprocess technology/Chemical Eng. (2001) and Bachelors in Pharmacy (1998) and had been working across Industry, University and Government Research Institutes with 15 years of experience in Computational Biology.

In 2014 he joined UCB in the New Medicines IT team, currently leading the data integration, Image and ‘omics’ based data management and analytics. His research interest involves biological data mining and visualization, mathematical algorithm design, High Performance Scientific Computing and simulation modelling of biological systems. In addition, he is always looking for disruptive technologies such as next generation sequencing and post NGS target validation (e.g. ENCODE), NoSQL techniques for Data Integration (Neo4j, SAP-HANA, SciDB, MongoDB), Gene Signature based mapping for Drug repurposing and Causal Reasoning for target identification, Artificial intelligence and Machine Learning for RWE, digital/sensors data and biological imaging.

12:20 Networking Lunch

13:20 What is required for a DTx product to be successful?

Jessica is European Lead for the Digital Therapeutics Alliance. She is also Digital Health Manager on clinical trials and Big Data projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked 13+ years with the WHO on digital health projects for health system strengthening. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has a MSc from the Medical College of Georgia, an MA form the University of Trento (Italy) and is pursuing a PhD in BioMedicine at the University of Barcelona.

14:00 Healthcare 'Disruptors'

Dr. Shikta Das is an academic, data scientist and women in tech campaigner whose work focuses on providing evidence-based learning in medicine and the pharmaceutical sector. She has worked as a Data Analytics Specialist at Roche Pharmaceuticals, which is the world's third-largest pharmaceutical company, famous for its cancer and diabetes management drugs. She is also an honorary lecturer in Epidemiology and Data Science at University College London (UCL) where she leads metabolomics and data science research within the Medical Research Council's Life-Long Health and Ageing Group. She also teaches essential employability skills to MBBS and MSc Cardiovascular Students on Statistics and Epidemiology at UCL.

14:40 Afternoon Tea

Dr Anisimov is working in pharma industry since 2002. He is currently Principal Data Scientist, Center for Design & Analysis, Amgen, UK. In the past he also worked for GlaxoSmithKline and Quintiles (IQVIA).
Vladimir started his career in academia and served for 20 years as Professor & Head of Applied Statistics Department established by himself at Kiev National University, Ukraine. Received PhD and ScDr degrees and diploma of Professor in Applied Statistics, published 200 papers and several books, supervised 24 PhD theses. Industry recognized expert in clinical trial’s modelling. Led a numerous number of various projects and some EU and UK grants.

15:50 Chair’s Closing Remarks and Close of Day One

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

9:10 AI for Life

Nicholas Kelley is the Data Science & A.I. advisor to the Digital Office. His role is to both identify and pair opportunities with innovative solutions across the pipeline and is leading a number of cross-company initiatives with the single goal of elevating data science at Novartis. These include organic and inorganic capability building, targeted external engagement, community building and new modes of operating to empower data scientists to impact the business in new innovative ways and better develop and attract talent - in addition to his key role in connecting and bringing in new innovative technologies.

Nick has a background as a data science practitioner with a Ph.D. in Biophysics from the Stanford School of Medicine with career experience in computational biology, chem- and bioinformatics, and most recently in the application of A.I. and machine learning in health.

• the potential of A.I. in health and the opportunities across the pharma pipeline
• concrete project examples from discovery through clinical trials and commercial, leveraging fundamental a.i. capabilities in cheminformatics, medical imaging, and NLP.
• the challenges & foundation required for data scientists to make a.i. opportunities a reality

9:50 Partnering for Digital Transformation – A Way Forward

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

• Evaluating the role of pharma-digital partnering for adopting new technologies and enabling "Pharma 4.0"
• Discussing the opportunities and efficiencies in partnering to drive new capabilities and digital transformation in pharma
• Reflecting on the challenges associated with digital partnering and discussing strategies to reduce risk
• Personal reflections and lessons learned on digital partnering and the way forward

10:30 Morning Coffee

11:00 International insight into Standards for seamless adoption of Prescription Digital Therapeutics

Mark Campbell is a senior healthcare manager with special interests in innovative technologies and health technology assessment. He now works as a freelance
expert having been responsible until March 2019 for NICE’s devices, diagnostics and digital evaluation programmes for almost 10 years. Before that he worked at Director
level in a UK NHS payer organisation and was a member of NICE’s technology appraisal committee. He originally qualified as a pharmacist and has worked in drug
and poisons information services, medicines management and medicines utilisation research. Current special interests include evidence development and evaluation of digital health technologies (DHTs), including artificial intelligence and prior to leaving
NICE he was part of the group which developed the first evidence standards for DHTs.

• Overviewing current FDA guidelines relating to PDG
• Gaining insight into European and UK perspectives - MHRA, NICE and EMA guidelines for PDG
• Evidence considerations for PDGs
• Discussing the need for aligning international regulations to ease adoption of PDG
• The importance of technical standards for acceptance of PDGs

11:40 Implementation eats strategy for breakfast

Bram van Leeuwen is Lead digital innovation BeNeLux for Sanofi. During his work at the Parnassia Bavo Groep (mental healthcare organization) he has lead one of the largest eHealth implementations in Europe. After his time at the Parnassia Bavo Groep he became director of a consultancy firm specialized on healthcare innovation. In his current role he is focusing on improving outcomes for patients in combination with smart digital solutions.

80% of innovations don’t scale to the doctor’s office

Patient and nurse included development is key to success

Implementation is not a project, you need a change model, or you will end up frustrated

Define your change strategy based on the topic, location, therapeutic area and your timeframe

12:20 Networking Lunch

13:20 Medical devices in the Digital Era - an Internet of Medical Things

Over the past nine years Ian has been working in various segments of the healthcare industry, throughout this time he has been utilizing big data, cutting-edge software and novel technology to find solutions to questions from all ranges of customers from line functions to senior management. Prior to Novartis, he worked in a variety of roles in healthcare, focusing primarily on scientific research and process optimization.

• Outlining a brief history of medical devices and digitalization
• Exploring how IoT is revolutionizing the industry landscape
• Discussing devices and their role in the emerging healthcare ecosystem
• Assessing the regulatory considerations of connectivity

14:00 Value Based Healthcare; The role of technology and its implications on Pharma

Umair Aslam is a Health Economist and Technology Strategist with deep insights about how new technology is bringing forward solutions, tools and frameworks that are transforming the health care and the future way of operating and creating value. Currently, he is working in the pharmaceutical industry for MSD Norway, where he is leading the work to bring forward innovative digital solutions that support better patient outcomes, address system inefficiencies and drive business value.

• The health care sector is slowly moving from volume-based care to value-based care, where healthcare providers are rewarded/reimbursed by the value or outcome they create and not based on the volume
• What are the potential implications on related industries such as Pharma, MedTech and others?
• What is the role of technology and e-Health in such a world?
• How does this affect the concept of user and patient centricity?

14:40 Afternoon Tea

15:10 Real-world Example of Disruptive Technologies in Pharma

James is a Medtech leader with an international track record of successful start-up, turnaround, mergers and exits. He started out as a software engineer before moving on to study medicine at University College London. He has over 20 years of hands on medical experience that ranges from hospital and primary care through to national and international medical director roles.

James has a specific interest in device companies working with big data and artificial intelligence solutions internationally. Today James is the CEO at Cambridge Respiratory Innovations Limited who has developed a world first connected hand held big data respiratory device.

15:50 Chair’s Closing Remarks and Close of Day Two

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

FEATURED SPEAKERS

Bhushan Bonde is the Head of Innovation Development at IT-NewMeds, UCB. He received PhD in Systems Biology and Mathematical Modelling, with an interdisciplinary background of Computing, Biology and Mathematical Biology from Oxford (2006). He also had an interdisciplinary M. Tech in Bioprocess technology/Chemical Eng. (2001) and Bachelors in Pharmacy (1998) and had been working across Industry, University and Government Research Institutes with 15 years of experience in Computational Biology.

In 2014 he joined UCB in the New Medicines IT team, currently leading the data integration, Image and ‘omics’ based data management and analytics. His research interest involves biological data mining and visualization, mathematical algorithm design, High Performance Scientific Computing and simulation modelling of biological systems. In addition, he is always looking for disruptive technologies such as next generation sequencing and post NGS target validation (e.g. ENCODE), NoSQL techniques for Data Integration (Neo4j, SAP-HANA, SciDB, MongoDB), Gene Signature based mapping for Drug repurposing and Causal Reasoning for target identification, Artificial intelligence and Machine Learning for RWE, digital/sensors data and biological imaging.

Nicholas Kelley is the Data Science & A.I. advisor to the Digital Office. His role is to both identify and pair opportunities with innovative solutions across the pipeline and is leading a number of cross-company initiatives with the single goal of elevating data science at Novartis. These include organic and inorganic capability building, targeted external engagement, community building and new modes of operating to empower data scientists to impact the business in new innovative ways and better develop and attract talent - in addition to his key role in connecting and bringing in new innovative technologies.

Nick has a background as a data science practitioner with a Ph.D. in Biophysics from the Stanford School of Medicine with career experience in computational biology, chem- and bioinformatics, and most recently in the application of A.I. and machine learning in health.

Dr Anisimov is working in pharma industry since 2002. He is currently Principal Data Scientist, Center for Design & Analysis, Amgen, UK. In the past he also worked for GlaxoSmithKline and Quintiles (IQVIA).
Vladimir started his career in academia and served for 20 years as Professor & Head of Applied Statistics Department established by himself at Kiev National University, Ukraine. Received PhD and ScDr degrees and diploma of Professor in Applied Statistics, published 200 papers and several books, supervised 24 PhD theses. Industry recognized expert in clinical trial’s modelling. Led a numerous number of various projects and some EU and UK grants.

Over the past nine years Ian has been working in various segments of the healthcare industry, throughout this time he has been utilizing big data, cutting-edge software and novel technology to find solutions to questions from all ranges of customers from line functions to senior management. Prior to Novartis, he worked in a variety of roles in healthcare, focusing primarily on scientific research and process optimization.

James is a Medtech leader with an international track record of successful start-up, turnaround, mergers and exits. He started out as a software engineer before moving on to study medicine at University College London. He has over 20 years of hands on medical experience that ranges from hospital and primary care through to national and international medical director roles.

James has a specific interest in device companies working with big data and artificial intelligence solutions internationally. Today James is the CEO at Cambridge Respiratory Innovations Limited who has developed a world first connected hand held big data respiratory device.

Jessica is European Lead for the Digital Therapeutics Alliance. She is also Digital Health Manager on clinical trials and Big Data projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked 13+ years with the WHO on digital health projects for health system strengthening. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has a MSc from the Medical College of Georgia, an MA form the University of Trento (Italy) and is pursuing a PhD in BioMedicine at the University of Barcelona.

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

Mark Campbell is a senior healthcare manager with special interests in innovative technologies and health technology assessment. He now works as a freelance
expert having been responsible until March 2019 for NICE’s devices, diagnostics and digital evaluation programmes for almost 10 years. Before that he worked at Director
level in a UK NHS payer organisation and was a member of NICE’s technology appraisal committee. He originally qualified as a pharmacist and has worked in drug
and poisons information services, medicines management and medicines utilisation research. Current special interests include evidence development and evaluation of digital health technologies (DHTs), including artificial intelligence and prior to leaving
NICE he was part of the group which developed the first evidence standards for DHTs.

Umair Aslam is a Health Economist and Technology Strategist with deep insights about how new technology is bringing forward solutions, tools and frameworks that are transforming the health care and the future way of operating and creating value. Currently, he is working in the pharmaceutical industry for MSD Norway, where he is leading the work to bring forward innovative digital solutions that support better patient outcomes, address system inefficiencies and drive business value.

Bhushan Bonde

Head of IT - Early Solution Innovation Development, UCB

Bhushan Bonde is the Head of Innovation Development at IT-NewMeds, UCB. He received PhD in Systems Biology and Mathematical Modelling, with an interdisciplinary background of Computing, Biology and Mathematical Biology from Oxford (2006). He also had an interdisciplinary M. Tech in Bioprocess technology/Chemical Eng. (2001) and Bachelors in Pharmacy (1998) and had been working across Industry, University and Government Research Institutes with 15 years of experience in Computational Biology.

In 2014 he joined UCB in the New Medicines IT team, currently leading the data integration, Image and ‘omics’ based data management and analytics. His research interest involves biological data mining and visualization, mathematical algorithm design, High Performance Scientific Computing and simulation modelling of biological systems. In addition, he is always looking for disruptive technologies such as next generation sequencing and post NGS target validation (e.g. ENCODE), NoSQL techniques for Data Integration (Neo4j, SAP-HANA, SciDB, MongoDB), Gene Signature based mapping for Drug repurposing and Causal Reasoning for target identification, Artificial intelligence and Machine Learning for RWE, digital/sensors data and biological imaging.

Bram Van Leeuwen

Lead Digital Innovation, Sanofi BeNeLux

Bram van Leeuwen is Lead digital innovation BeNeLux for Sanofi. During his work at the Parnassia Bavo Groep (mental healthcare organization) he has lead one of the largest eHealth implementations in Europe. After his time at the Parnassia Bavo Groep he became director of a consultancy firm specialized on healthcare innovation. In his current role he is focusing on improving outcomes for patients in combination with smart digital solutions.

Dr Nicholas Kelley

Data Science and AI Technical Advisor, Novartis

Nicholas Kelley is the Data Science & A.I. advisor to the Digital Office. His role is to both identify and pair opportunities with innovative solutions across the pipeline and is leading a number of cross-company initiatives with the single goal of elevating data science at Novartis. These include organic and inorganic capability building, targeted external engagement, community building and new modes of operating to empower data scientists to impact the business in new innovative ways and better develop and attract talent - in addition to his key role in connecting and bringing in new innovative technologies.

Nick has a background as a data science practitioner with a Ph.D. in Biophysics from the Stanford School of Medicine with career experience in computational biology, chem- and bioinformatics, and most recently in the application of A.I. and machine learning in health.

Dr Vladimir Anisimov

Principal Data Scientist , Amgen

Dr Anisimov is working in pharma industry since 2002. He is currently Principal Data Scientist, Center for Design & Analysis, Amgen, UK. In the past he also worked for GlaxoSmithKline and Quintiles (IQVIA).
Vladimir started his career in academia and served for 20 years as Professor & Head of Applied Statistics Department established by himself at Kiev National University, Ukraine. Received PhD and ScDr degrees and diploma of Professor in Applied Statistics, published 200 papers and several books, supervised 24 PhD theses. Industry recognized expert in clinical trial’s modelling. Led a numerous number of various projects and some EU and UK grants.

Ian Wallace

Device Manager, Novartis

Over the past nine years Ian has been working in various segments of the healthcare industry, throughout this time he has been utilizing big data, cutting-edge software and novel technology to find solutions to questions from all ranges of customers from line functions to senior management. Prior to Novartis, he worked in a variety of roles in healthcare, focusing primarily on scientific research and process optimization.

James Whitticase

CEO, Cambridge Innovation Limited

James is a Medtech leader with an international track record of successful start-up, turnaround, mergers and exits. He started out as a software engineer before moving on to study medicine at University College London. He has over 20 years of hands on medical experience that ranges from hospital and primary care through to national and international medical director roles.

James has a specific interest in device companies working with big data and artificial intelligence solutions internationally. Today James is the CEO at Cambridge Respiratory Innovations Limited who has developed a world first connected hand held big data respiratory device.

Jessica Shull

European Lead, Digital Therapeutics Alliance

Jessica is European Lead for the Digital Therapeutics Alliance. She is also Digital Health Manager on clinical trials and Big Data projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked 13+ years with the WHO on digital health projects for health system strengthening. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has a MSc from the Medical College of Georgia, an MA form the University of Trento (Italy) and is pursuing a PhD in BioMedicine at the University of Barcelona.

Karl Hess

Managing Director, OnDigitalHealth Consulting

Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well as a subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies, having interacted directly with hundreds of digital health companies over the last 10 years. Karl is currently Founding Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry. OnDigitalHealth Consulting provides management consulting services to any entity looking to take their digital health offering to the next level.

Mark Campbell

Freelance Expert , formerly of NICE

Mark Campbell is a senior healthcare manager with special interests in innovative technologies and health technology assessment. He now works as a freelance
expert having been responsible until March 2019 for NICE’s devices, diagnostics and digital evaluation programmes for almost 10 years. Before that he worked at Director
level in a UK NHS payer organisation and was a member of NICE’s technology appraisal committee. He originally qualified as a pharmacist and has worked in drug
and poisons information services, medicines management and medicines utilisation research. Current special interests include evidence development and evaluation of digital health technologies (DHTs), including artificial intelligence and prior to leaving
NICE he was part of the group which developed the first evidence standards for DHTs.

Professor Brian D. Smith

Principal Advisor, Pragmedic Limited

Professor Brian D Smith is the world’s leading authority on the evolution of the life sciences industry. At the University of Hertfordshire and Bocconi University, his research group uses Darwinian science to the understand the speciation of business models in the life sciences. His more than 300 articles and books include “The Future of Pharma”, “Brand Therapy”, “Darwin’s Medicine” and, most recently “Leadership in the Life Sciences”. Prior to his academic career, Brian worked in pharma and medtech for 20 years as a Research Chemist and in commercial roles. He continues to advise many of the industry’s leading firms.

Shikta Das

Senior Data Scientist, Independent

Dr. Shikta Das is an academic, data scientist and women in tech campaigner whose work focuses on providing evidence-based learning in medicine and the pharmaceutical sector. She has worked as a Data Analytics Specialist at Roche Pharmaceuticals, which is the world's third-largest pharmaceutical company, famous for its cancer and diabetes management drugs. She is also an honorary lecturer in Epidemiology and Data Science at University College London (UCL) where she leads metabolomics and data science research within the Medical Research Council's Life-Long Health and Ageing Group. She also teaches essential employability skills to MBBS and MSc Cardiovascular Students on Statistics and Epidemiology at UCL.

Umair Aslam

e-health Lead, MSD Norway

Umair Aslam is a Health Economist and Technology Strategist with deep insights about how new technology is bringing forward solutions, tools and frameworks that are transforming the health care and the future way of operating and creating value. Currently, he is working in the pharmaceutical industry for MSD Norway, where he is leading the work to bring forward innovative digital solutions that support better patient outcomes, address system inefficiencies and drive business value.

Viktoria Wegscheider

Business Development, Innerspace GmbH

Viktoria Wegscheider is Business Development Specialist at Innerspace – The Deep Training Company. She is the voice of the customer in her company and responsible for use case evaluations of DeepTraining in Virtual Reality. Trained as a graduate researcher in Human Computer Interaction and a Master in IT-Management, she has gained experience in the medical device and pharmaceutical industry. Today, her core competence focuses on the evaluation of potential training use cases for experience-based trainings (e.g. Virtual Reality technology) that lead to high transfer efficacy for the pharmaceutical industry. Innerspace – The DeepTraining Company brings a new, psychologically profound and technologically advanced approach to design and implement trainings on the market. The DeepTraining approach is centered around the “Human Error” and is designed to prevent them in aseptic manufacturing in an effective and efficient way.

Sponsors

View detailsInnerspaceSponsorshttps://www.innerspace.eu/Innerspace develops revolutionary training systems, in which aseptic production employees learn to master the key moments of their work. Innerspace uses high end Virtual Reality technology to implement research breakthroughs in Human Error Analysis and Transfer research into a powerful DeepTraining system. The DeepTrainings modules offer safe environments for repeatable, focused virtual experiences that create real, goal driven work experience. In addition, the Training Management System supports documentation and integration of training data. All that allows Innerspace to support its customers with a cutting-edge digital solution to train employees in one of the most critical fields of human interaction in aseptic manufacturing.

Exhibitors

Introhive was founded in New Brunswick, Canada in 2012 and has now grown to 200+ employees in 8 offices across North America, UK and India. Introhive provides an advanced Enterprise Relationship Management Platform that works with your current business platform to accelerate growth and provide insights into business relationships. Introhive integrates your account, contact, lead and opportunity records with the ubiquitous mobile and email platforms your organisation prefers to use.

As firms today rely on relationships to retain clients and grow their businesses, Introhive operates by linking and scoring the customer data you already have and passively collect the data that your teams uncover on a day to day basis. By understanding the “who knows who” across the business, Introhive will automatically map, score and share client insights across the firm to identify new opportunities for warm introductions, cross-selling or up selling opportunities. The net outcome is not only higher quality information in CRM, but a 360 degree view of how well your organisation truly knows your clients.

Lead Media Partner

ONdrugDelivery Magazine

Lead Media Partners

ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

Key Media Partners

View detailsBio Pharma TrendKey Media Partnershttps://www.biopharmatrend.com/BiopharmaTrend is a market and business intelligence platform for drug discovery and biotech industry, focusing on emerging areas: artificial intelligence in pharmaceutical R&D, "digitalization" of the pharma industry, and technology/business trends in pre-clinical and clinical drug development. We also publish articles, commentaries and opinions contributed by top industry professionals.

View detailsInternational Pharmaceutical Industry (IPI)Key Media Partnershttp://ipimediaworld.com/IPI – International Pharmaceutical Industry
IPI – was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.
Edited by our carefully selected editorial advisory panel, and extensive research network, IPI provides a proven supportive means of communication to the pharmaceutical, bio pharmaceutical, nutraceutical and medical devices industry the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies which will enable them to be more efficient, bring products to market faster, reduce cost and make healthcare accessible to all.

View detailspharmaphorumKey Media Partnershttp://www.pharmaphorum.compharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington.

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow.

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel.

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event.

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee.

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.

Speaker Interview with Jessica Shull

Interview With Karl Hess

Speaker List

Programme Highlights

Disruptive Tech in Pharma Brochure

Sponsors

Innerspace

Innerspace develops revolutionary training systems, in which aseptic production employees learn to master the key moments of their work. Innerspace uses high end Virtual Reality technology to implement research breakthroughs in Human Error Analysis and Transfer research into a powerful DeepTraining system. The DeepTrainings modules offer safe environments for repeatable, focused virtual experiences that create real, goal driven work experience. In addition, the Training Management System supports documentation and integration of training data. All that allows Innerspace to support its customers with a cutting-edge digital solution to train employees in one of the most critical fields of human interaction in aseptic manufacturing.

Exhibitors

introhive

Introhive was founded in New Brunswick, Canada in 2012 and has now grown to 200+ employees in 8 offices across North America, UK and India. Introhive provides an advanced Enterprise Relationship Management Platform that works with your current business platform to accelerate growth and provide insights into business relationships. Introhive integrates your account, contact, lead and opportunity records with the ubiquitous mobile and email platforms your organisation prefers to use.

As firms today rely on relationships to retain clients and grow their businesses, Introhive operates by linking and scoring the customer data you already have and passively collect the data that your teams uncover on a day to day basis. By understanding the “who knows who” across the business, Introhive will automatically map, score and share client insights across the firm to identify new opportunities for warm introductions, cross-selling or up selling opportunities. The net outcome is not only higher quality information in CRM, but a 360 degree view of how well your organisation truly knows your clients.

Media Partners

pharmaphorum

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

International Pharmaceutical Industry (IPI)

IPI – International Pharmaceutical Industry
IPI – was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.
Edited by our carefully selected editorial advisory panel, and extensive research network, IPI provides a proven supportive means of communication to the pharmaceutical, bio pharmaceutical, nutraceutical and medical devices industry the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies which will enable them to be more efficient, bring products to market faster, reduce cost and make healthcare accessible to all.

Bio Pharma Trend

BiopharmaTrend is a market and business intelligence platform for drug discovery and biotech industry, focusing on emerging areas: artificial intelligence in pharmaceutical R&D, "digitalization" of the pharma industry, and technology/business trends in pre-clinical and clinical drug development. We also publish articles, commentaries and opinions contributed by top industry professionals.

SAVE TO

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington.

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow.

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel.

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event.

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee.

Cookie Policy

From May 2011 a new privacy law came into effect across the EU. The law requires
that websites ask visitors for consent to use most web cookies. We use cookies to
ensure you get the best experience on our website –Tick here to accept cookie use
Details of our cookie use may be found here.

WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy,
which maintains that in order to be effective, learning should be organised and
structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional
competence’

CPD is a common requirement of individual membership with professional bodies and
Institutes. Increasingly, employers also expect their staff to undertake regular
CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do
not become obsolete, and allows for best practice and professional standards to
be upheld.

CPD can be undertaken through a variety of learning activities including instructor
led training courses, seminars and conferences, e:learning modules or structured
reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with
a collective membership of circa 4 million professionals, and they all expect their
members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked
to a licence to practice, for others it’s obligatory. By ensuring that their members
undertake CPD, the professional bodies seek to ensure that professional standards,
legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide
online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’
or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve
within a given time period. These schemes can also use different ‘currencies’ such
as points, merits, units or credits, where an individual must accumulate the number
required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of
learning.

‘Output’ based schemes are learner centred. They require individuals to set learning
goals that align to professional competencies, or personal development objectives.
These schemes also list different ways to achieve the learning goals e.g. training
courses, seminars or e:learning, which enables an individual to complete their CPD
through their preferred mode of learning.

As a formal provider of CPD certified activities, SMI Group can provide an indication
of the learning benefit gained and the typical completion. However, it is ultimately
the responsibility of the delegate to evaluate their learning, and record it correctly
in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces
and looking to the UK to benchmark educational standards. The undertaking of CPD
is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk